Akums Drugs to host investor meet on Sept 2 in Mumbai
- Akums Drugs will host investors on September 2, 2026
- The event is part of the Ashwamedh – Elara India Dialogue
- The physical session will be held at Hyatt, Mumbai
- No unpublished price-sensitive information will be shared

*this image is generated using AI for illustrative purposes only.
Akums Drugs & Pharmaceuticals will participate in an investor and analysts meet scheduled for September 2, 2026. The event forms part of the Ashwamedh – Elara India Dialogue 2026 series.
The company confirmed the schedule in a disclosure filed with stock exchanges on August 25, 2026. The meet is set for 2:00 pm at the Hyatt in Santacruz East, Mumbai. It will be conducted as a physical group session.
Event Details
| Particulars | Details |
|---|---|
| Event Name | Ashwamedh – Elara India Dialogue 2026 |
| Date | September 2, 2026 |
| Time | 2:00 pm |
| Mode | Physical |
| Location | Hyatt, Santacruz East, Mumbai |
Regulatory Compliance
The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Akums stated that no unpublished price-sensitive information would be shared during the session.
Dharamvir Malik, Company Secretary and Compliance Officer, signed the intimation. The company noted that the schedule remains subject to change based on exigencies from either the investors or the firm.
Historical Stock Returns for Akums Drugs & Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.28% | +0.14% | +8.40% | +54.03% | +55.75% | -6.43% |
How might Akums Drugs' strategic roadmap presented at the dialogue influence its valuation multiples in the mid-cap pharma sector?
Will the management provide updated guidance on R&D pipeline milestones or new product launches post-September 2026?
How does Akums Drugs plan to address potential regulatory headwinds in key international markets during this investor interaction?


































